These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 26057410

  • 41. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW, Barillari G.
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [Abstract] [Full Text] [Related]

  • 42. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
    Dalén M, Hjemdahl P, Holmström M, Ivert T.
    Lakartidningen; 2014 Apr; 111(24):1064-8. PubMed ID: 25129916
    [No Abstract] [Full Text] [Related]

  • 43. A new era of anticoagulation.
    Hainaut PH.
    Acta Clin Belg; 2012 Apr; 67(6):394-8. PubMed ID: 23340143
    [No Abstract] [Full Text] [Related]

  • 44. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Lane DA, Wood K.
    Circulation; 2015 Apr 21; 131(16):e412-5. PubMed ID: 25901074
    [No Abstract] [Full Text] [Related]

  • 45. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.
    Thromb Haemost; 2012 Mar 21; 107(3):584-9. PubMed ID: 22186961
    [Abstract] [Full Text] [Related]

  • 46. [Management of direct action oral anticoagulants in the peri-operative period and invasive techniques].
    Llau JV, Ferrandis R, Castillo J, de Andrés J, Gomar C, Gómez-Luque A, Hidalgo F, Torres LM, participantes en el Foro de Consenso de la ESRA-España sobre «Fármacos que alteran la hemostasia».
    Rev Esp Anestesiol Reanim; 2012 Mar 21; 59(6):321-30. PubMed ID: 22633209
    [Abstract] [Full Text] [Related]

  • 47. The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
    Pfeilschifter W, Luger S, Brunkhorst R, Lindhoff-Last E, Foerch C.
    Cerebrovasc Dis; 2013 Mar 21; 36(2):115-9. PubMed ID: 24029592
    [Abstract] [Full Text] [Related]

  • 48. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV, Quinlan DJ, Dahl OE, Schulman S.
    Circ Cardiovasc Qual Outcomes; 2010 Nov 21; 3(6):652-60. PubMed ID: 20923996
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
    Steed MB, Swanson MT.
    Oral Maxillofac Surg Clin North Am; 2016 Nov 21; 28(4):515-521. PubMed ID: 27624772
    [Abstract] [Full Text] [Related]

  • 51. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
    Yadlapati A, Groh C, Passman R.
    Am J Cardiol; 2014 Apr 15; 113(8):1362-3. PubMed ID: 24576547
    [Abstract] [Full Text] [Related]

  • 52. Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
    Baglin T.
    Br J Haematol; 2013 Oct 15; 163(2):160-7. PubMed ID: 23937286
    [Abstract] [Full Text] [Related]

  • 53. New oral anticoagulants and oculoplastic surgery.
    Ing E, Douketis J.
    Can J Ophthalmol; 2014 Apr 15; 49(2):123-7. PubMed ID: 24767215
    [Abstract] [Full Text] [Related]

  • 54. [New clinical perspectives in the management of oral direct anticoagulant agents].
    Marco P, Zamorano JL, Chana F, Llau JV.
    Med Clin (Barc); 2014 Feb 20; 142(4):171-8. PubMed ID: 23866969
    [No Abstract] [Full Text] [Related]

  • 55. Reversal of oral anticoagulation.
    Thigpen JL, Limdi NA.
    Pharmacotherapy; 2013 Nov 20; 33(11):1199-213. PubMed ID: 23606318
    [Abstract] [Full Text] [Related]

  • 56. New oral anticoagulants: will they replace warfarin?
    Little JW.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 May 20; 113(5):575-80. PubMed ID: 22668618
    [Abstract] [Full Text] [Related]

  • 57. Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
    Miller MP, Trujillo TC, Nordenholz KE.
    Am J Emerg Med; 2014 Apr 20; 32(4):375-82. PubMed ID: 24512886
    [Abstract] [Full Text] [Related]

  • 58. [Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
    Moustafa F, Milhaud G, Dublanchet N, Lebreton A, Dutheil F, Schmidt J.
    J Mal Vasc; 2015 Feb 20; 40(1):1-9. PubMed ID: 25572151
    [Abstract] [Full Text] [Related]

  • 59. New anticoagulants: how to deal with treatment failure and bleeding complications.
    Kazmi RS, Lwaleed BA.
    Br J Clin Pharmacol; 2011 Oct 20; 72(4):593-603. PubMed ID: 21752066
    [Abstract] [Full Text] [Related]

  • 60. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
    Harenberg J, Marx S, Dahl OE, Marder VJ, Schulze A, Wehling M, Weiss C.
    Thromb Haemost; 2012 Nov 20; 108(5):903-12. PubMed ID: 23014668
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.